No profile data available.
United Therapeutics Corporation (UTHR) is a healthcare company in the blood vessel treatment pharmaceuticals industry, based in Silver Spring, United States, with about 1,400 full-time employees.
It reported revenue of $3.18 billion for fiscal year 2025, up 10.6% from fiscal year 2024, and net income of $1.33 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $783.30 million, down 1.9% from a year before. United States was its largest region in fiscal year 2025, with 95% of revenue. Its market capitalization was $23.55 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
United Therapeutics reported $3.18 billion in revenue for fiscal year 2025, up 10.6% from $2.88 billion in fiscal year 2024. In Q2 2026 revenue was $783.30 million.
United States: 95% of revenue by region in fiscal year 2025, followed by Rest of World (5%).
$23.55 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood vessel treatment pharmaceuticals) include Liquidia Corporation (LQDA), Mineralys Therapeutics, Inc. (MLYS), Palvella Therapeutics, Inc. (PVLA), Gossamer Bio, Inc. (GOSS).